Operating cash flow of $87.7M in Q2 2026 was only 57% of net income, with working capital absorbing $143.5M, indicating cash conversion is strained by inventory and receivables buildup despite a low 5.2% capex-to-revenue ratio.
Astera Labs, Inc. Common Stock (ALAB) cash flow statement — 4-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 |
|---|
| Cash from Operations | 335.71M | 319.31M | 136.68M | -12.72M | -35.9M |
| Operating CF Margin % | - | 37.45% | 34.49% | -10.98% | -44.94% |
| Operating CF Growth % | 737.99% | 133.62% | 1174.83% | 64.58% | - |
| Net Income | 369.49M | 219.13M | -83.42M | -26.26M | -58.34M |
| Depreciation & Amortization | 11.95M | 6.83M | 3.15M | 1.78M | 807K |
| Stock-Based Compensation | 195.02M | 160.03M | 234.59M | 10.68M | 30.23M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 10.31M | -726K | -4.35M | 10.76M | 1.38M |
| Working Capital Changes | -251.06M | -65.96M | -13.29M | -9.68M | -9.97M |
| Change in Receivables | -168.29M | -44.34M | -30.48M | 2.39M | -6.04M |
| Change in Inventory | -51.5M | -12.95M | -19.29M | -5.56M | -19.36M |
| Change in Payables | 12.4M | 14.19M | 20.89M | -4.26M | 2.13M |
| Cash from Investing | -399.4M | -241.47M | -757.57M | -17.77M | -90.59M |
| Capital Expenditures | -59.04M | -37.54M | -34.24M | -2.76M | -3.87M |
| CapEx % of Revenue | 4.91% | 4.4% | 8.64% | 2.38% | 4.85% |
| Acquisitions | -98M | -28.79M | 0 | 0 | 0 |
| Investments | - | - | - | - | - |
| Other Investing | -3M | -500K | -1.41M | 0 | 0 |
| Cash from Financing | 11.81M | 9.8M | 655.84M | -502K | 151.67M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 20.5M | 9.8M | 671.13M | -210K | 149.55M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | -1.07M | -210K | -313K |
| Other Financing | -8.69M | 0 | -15.29M | -292K | 2.12M |
| Net Change in Cash | -51.95M | 87.64M | 34.95M | -30.99M | 25.18M |
| Free Cash Flow | 276.68M | 281.76M | 102.43M | -15.48M | -39.77M |
| FCF Margin % | 23.02% | 33.05% | 25.85% | -13.37% | -49.79% |
| FCF Growth % | 31.52% | 175.07% | 761.83% | 61.08% | - |
| FCF per Share | 1.52 | 1.57 | 0.78 | -0.10 | -0.30 |
| FCF Conversion (FCF/Net Income) | 0.75x | 1.46x | -1.64x | 0.48x | 0.62x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 7.79M | 2.48M | 0 |
Quick answers to the most common questions about buying ALAB stock.
Astera Labs, Inc. Common Stock (ALAB) generated $319.3M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Astera Labs, Inc. Common Stock (ALAB) generated $281.8M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Astera Labs, Inc. Common Stock (ALAB) spent $37.5M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Extreme valuation and insider selling
Metrics are mathematically derived from official filings.
Cash Conversion Lags Reported Earnings
In Q2 2026, ALAB's operating cash flow of $87.7M was only 57% of net income, as reported in SEC filings, with working capital absorbing $143.5M, suggesting earnings quality is strained by rapid growth.
The OCF/NI ratio of 0.57 in Q2 2026, down from 0.93 in Q1, indicates that reported net income is not fully translating into cash. The significant working capital outflow of $143.5M, likely tied to inventory and receivables buildup for AI infrastructure, may signal that cash conversion will remain pressured as long as growth continues at this pace. Investors should monitor whether this gap narrows as revenue growth normalizes.
FCF Margin Volatility Reflects Scaling
Free cash flow margin swung from 3.7% in Q1 2025 to 69.5% in Q2 2025, then settled at 17.1% in Q2 2026, based on reported figures, indicating that FCF generation is highly sensitive to working capital swings.
The erratic FCF margin trajectory, with a peak of 69.5% in Q2 2025, suggests that the company's cash generation is not yet stable. The recent 17.1% margin in Q2 2026, while respectable, is below the 28%+ levels seen in late 2025, implying that growth is consuming cash. This volatility may indicate that the business model requires significant working capital investment to support its rapid expansion, which could temper future FCF growth.
Capital Intensity Remains Low
Capital expenditures averaged only 5.2% of revenue in Q2 2026, as per financial statements, reflecting a fabless model that requires minimal fixed asset investment, allowing most cash flow to be reinvested in R&D.
With CapEx/Revenue at 5.2% in Q2 2026, down from 10.9% in Q4 2024, Astera Labs demonstrates a highly asset-light model. This low capital intensity suggests that the company can scale revenue without proportionate increases in fixed assets, which is a positive for future FCF generation. However, the modest CapEx may also indicate that the company is not investing heavily in internal manufacturing capabilities, relying instead on foundry partners.
Working Capital Swings Signal Inventory Build
Working capital changes were a negative $143.5M in Q2 2026, as reported in cash flow statements, the largest outflow in the past ten quarters, suggesting significant inventory and receivables buildup to support AI cluster demand.
The substantial working capital outflow in Q2 2026, following a $59.1M outflow in Q1, indicates that Astera Labs is aggressively building inventory and extending credit to customers, likely to secure supply for hyperscaler orders. This pattern may reflect a strategic decision to buffer against supply chain constraints, but it also ties up cash and could lead to write-downs if demand softens. The efficiency of collections and inventory turnover warrants close monitoring.
No Capital Returns, Cash for Growth
Astera Labs paid no dividends and made no buybacks in Q2 2026, as per cash flow data, instead using cash for acquisitions and R&D, indicating a reinvestment-focused capital allocation strategy.
The absence of shareholder returns, combined with $4.2M in acquisition-related outflows in Q2 2026, suggests that management is prioritizing growth investments over returning capital. This is typical for a high-growth company, but the lack of buybacks may also reflect a belief that the stock is overvalued. Investors should watch for any shift toward capital returns as growth matures.
Cumulative Cash Generation Lags Net Income
Over the last ten quarters, cumulative operating cash flow of $618.4M is below cumulative net income of $569.5M, as per reported data, indicating that earnings have not yet fully converted to cash.
The cumulative gap between net income and operating cash flow, though small, suggests that a portion of reported profits is tied up in working capital. This divergence is common in high-growth companies, but the magnitude of the working capital swings—particularly the $143.5M outflow in Q2 2026—implies that cash conversion may remain challenged. If this trend persists, it could signal that earnings quality is lower than headline numbers suggest.
What Could Invalidate the Base Case
The cash flow statement may obscure the impact of stock-based compensation, which totaled $64M in Q2 2026, as per reported data, potentially overstating cash generation relative to shareholder dilution.
While operating cash flow appears robust, the significant SBC expense, which is added back in the cash flow statement, suggests that actual cash earnings are lower than reported. Additionally, the working capital outflows may be masking a slowdown in collections or an inventory overbuild that could reverse. Investors should scrutinize whether the company's cash conversion improves as growth normalizes, or if the gap between net income and operating cash flow signals a structural issue.